I realised I never really did a post about who I am, or for the new followers here that don't know me:
I'm Calum, 29, from the UK.
Self-employed since 17 as a graphic and web designer. No inherited money, no trust fund, just years of client work turned into savings and then investments.
Why I invest:
- Not to look wealthy, to actually become wealthy
- Financial freedom is the real goal, not flexing a number
- Time and optionality matter more to me than stuff
My journey so far:
- Bought Bitcoin at 18, way before I understood anything about markets
- Started picking individual stocks properly at 22 (felt late)
- Long-only, no leverage, no options, no shorting
- Aim to max my UK Stocks and Shares ISA every year
- Made plenty of mistakes along the way ($CRSR still haunts me, sold $MU way too early)
- Building Chartloom as part of my journey
Current portfolio:
- 13 individual stocks, no ETFs
- Led by $AMD and $TSLA as my two highest conviction positions
- Rounded out by names like $AMZN, $META, $DUOL, $HIMS, $NFLX
- Sitting around 10%~ cash, currently deploying aggressively this year.
Where I'm headed:
- Moving to South East Asia next year with GF
- Lower cost of living / maybe more to invest eventually.
- Building wealth doesn't have to mean staying in an expensive country you didn't choose
And why Chartloom exists:
I got tired of paying for or juggling multiple different tools just to research a stock properly. So I started building the platform I wished existed when I was 22 with no clue what I was doing.
Currently has free research tools for anyone, and a paid tier priced at a fraction of what the big incumbents charge for the same depth.
Still early, still building in public, still figuring a lot of it out as I go.
That's me. What do you want to know?
international was 9% of $HIMS revenue a year ago
in Q3 2026 it's 26%: $233M, up from $55M
domestic revenue still grew 21%, to $657M
excited to see how this looks by 2028 if they both can continue to grow fast
question for anyone who runs a small business
which hurts more:
> a site that looks dated
> a site that looks great but nobody gets in touch
asking because i'm building my agency's new site right now, and going deeper on fixing business problems. especially right now where AI slop is so obvious. It can instantly ruin your businesses trust.
only 8.6% of $DUOL's monthly users pay
Q3 2026: 13.1M subscribers out of 153.1M monthly users. a year earlier it was 8.5%
if just 1% more of them paid, that's ~1.5M extra subscribers
at ~$85 a year each, about $130M more subscription sales a year.
roughly +12% more annual recurring revenue with just a 1% conversion of MAU.
More than 10,000 people signed up for early access when we launched the waitlist two weeks ago for Peptides+. Starting today, they all have access to a comprehensive intake that will be the beginning of a journey with a provider to find whether a personalized treatment plan is right for them.
Clinically-guided protocols. At-home blood collection. The full support of a care team that knows you, your progress, and your goals. And 5 US-compounded treatments, with more to come soon.
Itโs exactly what we think health should be: easy, personal, high-quality, supported by independent experts, and on the cutting edge of where science is going.
We canโt wait to see where those journeys take you.
Read more here, including important info: https://t.co/ibSpL1tSEB
$HIMS launched peptides+ yesterday. 5 compounded treatments, sermorelin and NAD+ among them
10,000+ people joined the early access list
What I like:
- another angle that supports the "netflix of healthcare" idea
- it's their own product this time, not someone else's drug at someone else's price, so might be better margins again
- gives them ahead start on competitors and build SEO/AI authority for traffic
What bugs me:
- none of the 5 are FDA approved. the peptides that need the new HHS rules, like BPC-157, are still on hold, so nothing really that new here, but a first step
- their own CMO: "we don't have all of this data that we're used to having with compounds like this"
- not all of them are peptides listed, except for a small tagline badge for each to show which are and aren't.
They've said peptides won't be material to Q4, so don't see these particular SKUs having much material impact. so it's a 2027 thing at the earliest, if the rules hold. I hope they aren't getting themselves into any legal issues again with these
@weary_centurion Perhaps so. I think they can definitely move a few product SKUs to other channels, but most likely keep majority DTC. Call made it sound like something might be in the work
96% of $ODD's revenue is online direct to customers
Q3 2026: $138.7M of $145.0M
almost no retailer in between, so the ad account is the shop window. when ads wobble, the whole business feels it
that's been the main issue this year. hence the stock crash.
on the call, it sounded like they might be preparing to make some announcement soon or next year, maybe on amazon or perhaps retail?
the concern to me would be losing those customer-data points from the website forms/intake/onboarding, that's used to better match the customer with the products, as well as upselling + building customer profiles with AI + data. This gives them a lot of insight on what the customers need or are after. It's a very good advantage for $ODD over competitors that don't have this deep data on their customers. So moving to something like Amazon or another storefront, loses that connection.
$HIMS launched peptides+ yesterday. 5 compounded treatments, sermorelin and NAD+ among them
10,000+ people joined the early access list
What I like:
- another angle that supports the "netflix of healthcare" idea
- it's their own product this time, not someone else's drug at someone else's price, so might be better margins again
- gives them ahead start on competitors and build SEO/AI authority for traffic
What bugs me:
- none of the 5 are FDA approved. the peptides that need the new HHS rules, like BPC-157, are still on hold, so nothing really that new here, but a first step
- their own CMO: "we don't have all of this data that we're used to having with compounds like this"
- not all of them are peptides listed, except for a small tagline badge for each to show which are and aren't.
They've said peptides won't be material to Q4, so don't see these particular SKUs having much material impact. so it's a 2027 thing at the earliest, if the rules hold. I hope they aren't getting themselves into any legal issues again with these
From my quick AIO/AEO checks, credit karma shows up when people ask about it by name, but almost never for unbranded money questions. those answers go to nerdwallet, experian, forbes and wallethub. Definitely where I believe they want to put focus on $INTU
Congrats on the quarter @sasan_goodarzi
Pulled up https://t.co/XSDCUySm3A for a quick SEO/AEO/AIO check based on earnings call comments, and instantly hit an error page.
For site error; my guess looks like .com is sometimes sending UK visitors to an error page instead of redirecting them to .co.uk. Ends up showing old historical creditkarma site + breaking.
Another thing I instantly noticed, on mobile, navigation menu on the homepage is broken after scrolling.
@creditkarma
@WillBiddy_@sasan_goodarzi@Intuit Honestly did a quick glance over the site. A lot could be worked on, and I hope this is part of their plan
Canadian + UK sites need revamp. Looks like they are haven't had any updates in 2-3 years... Not what I'd like to see as an investor
Congrats on the quarter @sasan_goodarzi
Pulled up https://t.co/XSDCUySm3A for a quick SEO/AEO/AIO check based on earnings call comments, and instantly hit an error page.
For site error; my guess looks like .com is sometimes sending UK visitors to an error page instead of redirecting them to .co.uk. Ends up showing old historical creditkarma site + breaking.
Another thing I instantly noticed, on mobile, navigation menu on the homepage is broken after scrolling.
@creditkarma
a cost buried in UK share purchases: 0.5% stamp duty, taken automatically
ยฃ1,000 of a uk company costs ยฃ5 in tax before any fees
shares in foreign companies usually don't have it.
does this make you skip UK stocks?
personally a very small price to pay, but it would definitely add up over a lifetime of performance.
what people say about $DUOL: ai will eat it
what $DUOL reported for Q3 2026:
- gross margin 72.9%, up from 72.5% a year ago
- ahead of its own expectations
- the reason: lower ai costs and cheaper hosting
the cost of the thing everyone fears went down, the irony.
AI is accelerating everything inside the business, content creation, teaching quality, customer value, CURR, courses, time to deployment... etc.
Open source models and cost per token falling is super bullish for $DUOL and others with a distribution channel to a large audience.
I believe this will soon convert over the next few years into higher monetisation and be highly profitable.
$AMZN's AWS is about 23% of sales and about 63% of operating profit
Q3 2026: AWS made $17.8B of the $28.1B total, on $46.0B of sales. margin 38.7%
the rest of amazon earned $10.3B on $155.9B
Crazy how fast it's growing too. This will have massive operating leverage overtime for Amazon to reinvest into other initiatives and continue to build their moat and flywheel.
I checked and some are classed as a peptide, while others are usually categorised as a peptide (even if it ain't weirdly). If I was to guess, they are trying to get ahead start on competitors and capture as much SEO/AI authority as possible as a place to buy peptides.
but yeah it's disingenuous if they aren't exactly what people expected.
Even though it's a peptide page, I think they label them here which aren't a peptide, and again, I think it's a marketing/traffic play more than anything and launching a few products off the bat instead of just 1-2.
what people say about $DUOL: ai will eat it
what $DUOL reported for Q3 2026:
- gross margin 72.9%, up from 72.5% a year ago
- ahead of its own expectations
- the reason: lower ai costs and cheaper hosting
the cost of the thing everyone fears went down, the irony.
AI is accelerating everything inside the business, content creation, teaching quality, customer value, CURR, courses, time to deployment... etc.
Open source models and cost per token falling is super bullish for $DUOL and others with a distribution channel to a large audience.
I believe this will soon convert over the next few years into higher monetisation and be highly profitable.